Tiziana Napolitano

Biological Scientist at DiogenX

Tiziana Napolitano has a diverse work experience in the field of biological science. Tiziana began their career as a Studentessa Leonardo da Vinci at The Babraham Institute from November 2011 to June 2012. Tiziana then worked as an Assistant Researcher at the Max Delbrück Center for Molecular Medicine from October 2012 to June 2013. Tiziana then pursued their PhD at Université Nice Sophia Antipolis, where they worked as a PhD student from October 2013 to December 2017. Tiziana subsequently joined Inserm as a Postdoctoral Researcher from January 2018 to August 2020. Currently, they work as a Biological Scientist at DiogenX starting from September 2020.

Tiziana Napolitano completed their education with a Doctor of Philosophy - PhD degree in Life Sciences from Université Côte d'Azur between 2013 and 2017. Prior to that, they pursued their undergraduate studies at Università degli Studi di Napoli Federico II from 2003 to 2009, where they obtained a Laurea Specialistica in Biotecnologie Mediche with a focus on cellular and molecular biology, microbiology, biochemistry, diagnostics, pharmacology, and gene therapy.

In terms of additional certifications, Tiziana Napolitano received a Laboratory Animal Science certification in January 2014, although the institution that granted this certification is unspecified.

Their earlier education at Liceo classico "G. Carducci" does not specify any specific degree or field of study.

Location

Nice, France

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices


DiogenX

DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.


Industries

Headquarters

Marseille, France

Employees

1-10

Links